In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Q: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Right to Try Act''.

SEC. 2. USE OF UNAPPROVED MEDICAL PRODUCTS BY PATIENTS DIAGNOSED WITH A
TERMINAL ILLNESS.

(a) In General.--Notwithstanding the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 301 et seq.), the Controlled Substances Act (21
U.S.C. 801 et seq.), and any other provision of Federal law, the
Federal Government shall not take any action to prohibit or restrict--
(1) the production, manufacture, distribution, prescribing,
or dispensing of an experimental drug, biological product, or
device that--
(A) is intended to treat a patient who has been
diagnosed with a terminal illness; and
(B) is authorized by, and in accordance with, State
law; and
(2) the possession or use of an experimental drug,
biological product, or device--
(A) that is described in subparagraphs (A) and (B)
of paragraph (1); and
(B) for which the patient has received a
certification from the patient's treating physician in
accordance with subsection (b).
(b) Physician Certification.--A certification by the patient's
treating physician referred to in subsection (a)(2)(B) must include
each of the following:
(1) A certification that the physician--
(A) is in good standing with the physician's
certifying organization or board; and
(B) has personally examined the patient.
(2) A certification that there is no reason to conclude the
experimental drug, biological product, or device poses an
unreasonable and significant risk of danger to the patient.
(3) A certification that the patient has been diagnosed
with a terminal disease or condition and does not have any
treatment options that--
(A) are comparable to treatment using the
experimental drug, biological product, or device or
otherwise satisfactory; and
(B) are approved, licensed, or cleared for
commercial distribution under section 505, 510(k), or
515 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355, 360(k), 360(e)) or section 351 of the
Public Health Service Act (42 U.S.C. 262) and are
available to diagnose, monitor, or treat the patient's
disease or condition.
(4) A certification that the probable risk to the patient
from the experimental drug, biological product, or device is
not greater than the probable risk from the patient's disease
or condition.
(5) A certification that the physician has provided the
patient with a written statement and oral explanation of the
medical treatment to be provided using the experimental drug,
biological product, or device.
(6) An acknowledgement signed by the patient (or the
patient's legal representative) that the physician has provided
the written statement and oral explanation required by
paragraph (5), and has disclosed the following:
(A) That the medical treatment using the
experimental drug, biological product, or device is
experimental or nonconventional.
(B) That the experimental drug, biological product,
or device has not been approved, licensed, or cleared
for commercial distribution under section 505, 510(k),
or 515 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355, 360(k), 360(e)) or section 351 of the
Public Health Service Act (42 U.S.C. 262) for any
indication.
(C) The material risks generally recognized by a
reasonably prudent physician of the medical treatment's
side effects.
(D) An explanation of the medical treatment,
including the expected frequency and duration of the
treatment.
(c) No Liability or Use of Outcomes.--
(1) No liability.--Notwithstanding any other provision of
law, no liability shall lie against a producer, manufacturer,
distributor, prescriber, dispenser, possessor, or user of an
experimental drug, biological product, or device for the
production, manufacture, distribution, prescribing, dispensing,
possession, or use of an experimental drug, biological product,
or device that is in compliance, with subsection (a).
(2) No use of outcomes.--Notwithstanding any other
provision of law, the outcome of any production, manufacture,
distribution, prescribing, dispensing, possession, or use of an
experimental drug, biological product, or device that was done
in compliance with subsection (a) shall not be used by a
Federal agency reviewing the experimental drug, biological
product, or device to delay or otherwise adversely impact
review or approval of such experimental drug, biological
product, or device.
(d) Rules of Construction.--Nothing in this Act shall be construed
to--
(1) require a manufacturer or other person to make
available any experimental drug, biological product, or device;
or
(2) prohibit a manufacturer or other person from receiving
compensation or recovering costs for the production,
manufacture, distribution, or sale of an experiment drug,
biological product, or device.
(e) Definitions.--In this section:
(1) Biological product.--The term ''biological product''
has the meaning given to such term in section 351 of the Public
Health Service Act (42 U.S.C. 262).
(2) Device; drug.--The terms ''device'' and ''drug'' have
the meanings given to such terms in section 201 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 321).
(3) Experimental drug, biological product, or device.--The
term ''experimental drug, biological product, or device'' means
a drug, biological product, or device that--
(A) has successfully completed a phase 1 clinical
investigation;
(B) remains under investigation in a clinical trial
approved by the Food and Drug Administration; and
(C) is not approved, licensed, or cleared for
commercial distribution under section 505, 510(k), or
515 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355, 360(k), 360(e)) or section 351 of the
Public Health Service Act (42 U.S.C. 262).
(4) Phase 1 clinical investigation.--The term ''phase 1
clinical investigation'' means a phase 1 clinical
investigation, as described in section 312.21 of title 21, Code
of Federal Regulations (or any successor regulations).
(5) Terminal illness.--The term ''terminal illness'' has
the meaning given to such term in the State law specified in
subsection (a)(1)(B).

A: Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.
****
Q: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Tribal HUD-VASH Act of 2017''.

SEC. 2. RENTAL ASSISTANCE FOR HOMELESS OR AT-RISK INDIAN VETERANS.

Section 8(o)(19) of the United States Housing Act of 1937 (42
U.S.C. 1437f(o)(19)) is amended by adding at the end the following:
''(D) Indian veterans housing rental assistance
program.--
''(i) Definitions.--In this subparagraph:
''(I) Eligible indian veteran.--The
term 'eligible Indian veteran' means an
Indian veteran who is--
''(aa) homeless or at risk
of homelessness; and
''(bb) living--

''(AA) on or near a
reservation; or

''(BB) in or near
any other Indian area.

''(II) Eligible recipient.--The
term 'eligible recipient' means a
recipient eligible to receive a grant
under section 101 of the Native
American Housing Assistance and Self-
Determination Act of 1996 (25 U.S.C.
4111).
''(III) Indian; indian area.--The
terms 'Indian' and 'Indian area' have
the meanings given those terms in
section 4 of the Native American
Housing Assistance and Self-
Determination Act of 1996 (25 U.S.C.
4103).
''(IV) Indian veteran.--The term
'Indian veteran' means an Indian who is
a veteran.
''(V) Program.--The term 'Program'
means the Tribal HUD-VASH program
carried out under clause (ii).
''(VI) Tribal organization.--The
term 'tribal organization' has the
meaning given the term in section 4 of
the Indian Self-Determination and
Education Assistance Act (25 U.S.C.
5304).
''(ii) Program specifications.--The
Secretary shall use not less than 5 percent of
the amounts made available for rental
assistance under this paragraph to carry out a
rental assistance and supported housing
program, to be known as the 'Tribal HUD-VASH
program', in conjunction with the Secretary of
Veterans Affairs, by awarding grants for the
benefit of eligible Indian veterans.
''(iii) Model.--
''(I) In general.--Except as
provided in subclause (II), the
Secretary shall model the Program on
the rental assistance and supported
housing program authorized under
subparagraph (A) and applicable
appropriations Acts, including
administration in conjunction with the
Secretary of Veterans Affairs.
''(II) Exceptions.--
''(aa) Secretary of housing
and urban development.--After
consultation with Indian
tribes, eligible recipients,
and any other appropriate
tribal organizations, the
Secretary may make necessary
and appropriate modifications
to facilitate the use of the
Program by eligible recipients
to serve eligible Indian
veterans.
''(bb) Secretary of
veterans affairs.--After
consultation with Indian
tribes, eligible recipients,
and any other appropriate
tribal organizations, the
Secretary of Veterans Affairs
may make necessary and
appropriate modifications to
facilitate the use of the
Program by eligible recipients
to serve eligible Indian
veterans.
''(iv) Eligible recipients.--The Secretary
shall make amounts for rental assistance and
associated administrative costs under the
Program available in the form of grants to
eligible recipients.
''(v) Funding criteria.--The Secretary
shall award grants under the Program based on--
''(I) need;
''(II) administrative capacity; and
''(III) any other funding criteria
established by the Secretary in a
notice published in the Federal
Register after consulting with the
Secretary of Veterans Affairs.
''(vi) Administration.--Grants awarded
under the Program shall be administered in
accordance with the Native American Housing
Assistance and Self-Determination Act of 1996
(25 U.S.C. 4101 et seq.), except that
recipients shall--
''(I) submit to the Secretary, in a
manner prescribed by the Secretary,
reports on the utilization of rental
assistance provided under the Program;
and
''(II) provide to the Secretary
information specified by the Secretary
to assess the effectiveness of the
Program in serving eligible Indian
veterans.
''(vii) Consultation.--
''(I) Grant recipients; tribal
organizations.--The Secretary, in
coordination with the Secretary of
Veterans Affairs, shall consult with
eligible recipients and any other
appropriate tribal organization on the
design of the Program to ensure the
effective delivery of rental assistance
and supportive services to eligible
Indian veterans under the Program.
''(II) Indian health service.--The
Director of the Indian Health Service
shall provide any assistance requested
by the Secretary or the Secretary of
Veterans Affairs in carrying out the
Program.
''(viii) Waiver.--
''(I) In general.--Except as
provided in subclause (II), the
Secretary may waive or specify
alternative requirements for any
provision of law (including
regulations) that the Secretary
administers in connection with the use
of rental assistance made available
under the Program if the Secretary
finds that the waiver or alternative
requirement is necessary for the
effective delivery and administration
of rental assistance under the Program
to eligible Indian veterans.
''(II) Exception.--The Secretary
may not waive or specify alternative
requirements under subclause (I) for
any provision of law (including
regulations) relating to labor
standards or the environment.
''(ix) Renewal grants.--The Secretary may--
''(I) set aside, from amounts made
available for tenant-based rental
assistance under this subsection and
without regard to the amounts used for
new grants under clause (ii), such
amounts as may be necessary to award
renewal grants to eligible recipients
that received a grant under the Program
in a previous year; and
''(II) specify criteria that an
eligible recipient must satisfy to
receive a renewal grant under subclause
(I), including providing data on how
the eligible recipient used the amounts
of any grant previously received under
the Program.
''(x) Reporting.--
''(I) In general.--Not later than 1
year after the date of enactment of the
Tribal HUD-VASH Act of 2017, and every
5 years thereafter, the Secretary, in
coordination with the Secretary of
Veterans Affairs and the Director of
the Indian Health Service, shall--
''(aa) conduct a review of
the implementation of the
Program, including any factors
that may have limited its
success; and
''(bb) submit a report
describing the results of the
review under item (aa) to--

''(AA) the
Committee on Indian
Affairs, the Committee
on Banking, Housing,
and Urban Affairs, the
Committee on Veterans'
Affairs, and the
Committee on
Appropriations of the
Senate; and

''(BB) the
Subcommittee on Indian,
Insular and Alaska
Native Affairs of the
Committee on Natural
Resources, the
Committee on Financial
Services, the Committee
on Veterans' Affairs,
and the Committee on
Appropriations of the
House of
Representatives.

''(II) Analysis of housing stock
limitation.--The Secretary shall
include in the initial report submitted
under subclause (I) a description of--
''(aa) any regulations
governing the use of formula
current assisted stock (as
defined in section 1000.314 of
title 24, Code of Federal
Regulations (or any successor
regulation)) within the
Program;
''(bb) the number of
recipients of grants under the
Program that have reported the
regulations described in item
(aa) as a barrier to
implementation of the Program;
and
''(cc) proposed alternative
legislation or regulations
developed by the Secretary in
consultation with recipients of
grants under the Program to
allow the use of formula
current assisted stock within
the Program.''.

Passed the Senate May 23, 2018.

Attest:

JULIE E. ADAMS,

Secretary.

A: Tribal HUD-VASH Act of 2017 (Sec. 2) This bill provides statutory authority for the Tribal HUD-VASH program, which provides rental assistance and supportive services to Indian veterans who are homeless or at risk of homelessness and living in or near an Indian area. The United States Housing Act of 1937 is amended to direct the Department of Housing and Urban Development (HUD) to use at least 5% of rental assistance amounts under the HUD-VASH program, which provides housing assistance to homeless veterans, for the Tribal HUD-VASH program. The Tribal HUD-VASH program shall be carried out in conjunction with the Department of Veterans Affairs (VA). HUD and the VA: (1) shall consult with tribal organizations regarding the program's design, and (2) may make program modifications after consulting with tribal organizations. Program grants shall be made to entities eligible for Native American housing assistance block grants. HUD may make renewal grants to entities that have received prior program grants.
****
Q: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Workplace Goods Job Growth and
Competitiveness Act of 2001''.

SEC. 2. STATUTE OF REPOSE FOR DURABLE GOODS USED IN A TRADE OR
BUSINESS.

(a) In General.--Except as otherwise provided in this Act--
(1) no civil action may be filed against the manufacturer
or seller of a durable good for damage to property arising out
of an accident involving that durable good if the accident
occurred more than 18 years after the date on which the durable
good was delivered to its first purchaser or lessee; and
(2) no civil action may be filed against the manufacturer
or seller of a durable good for damages for death or personal
injury arising out of an accident involving that durable good
if the accident occurred more than 18 years after the date on
which the durable good was delivered to its first purchaser or
lessee and if--
(A) the claimant has received or is eligible to
receive worker compensation; and
(B) the injury does not involve a toxic harm
(including, but not limited to, any asbestos-related
harm).
(b) Exceptions.--
(1) In general.--A motor vehicle, vessel, aircraft, or
train, that is used primarily to transport passengers for hire
shall not be subject to this Act.
(2) Certain express warranties.--This Act does not bar a
civil action against a defendant who made an express warranty
in writing as to the safety or life expectancy of a specific
product which was longer than 18 years, except that this Act
shall apply at the expiration of that warranty.
(3) Aviation limitations period.--This Act does not affect
the limitations period established by the General Aviation
Revitalization Act of 1994 (49 U.S.C. 40101 note).
(4) Actions involving the environment.--Subsection (a)(1)
does not supersede or modify any statute or common law that
authorizes an action for civil damages, cost recovery, or any
other form of relief for remediation of the environment (as
defined in section 101(8) of the Comprehensive Environmental
Response, Compensation, and Liability Act of 1980 (42 U.S.C.
9601(8)).
(c) Effect on State Law; Preemption.--Subject to subsection (b),
this Act preempts and supersedes any State law that establishes a
statute of repose to the extent such law applies to actions covered by
this Act. Any action not specifically covered by this Act shall be
governed by applicable State law.
(d) Transitional Provision Relating to Extension of Repose
Period.--To the extent that this Act shortens the period during which a
civil action could be otherwise brought pursuant to another provision
of law, the claimant may, notwithstanding this Act, bring the action
not later than 1 year after the date of the enactment of this Act.

SEC. 3. DEFINITIONS.

In this Act:
(1) Claimant.--The term ''claimant'' means any person who
brings an action covered by this Act and any person on whose
behalf such an action is brought. If such an action is brought
through or on behalf of an estate, the term includes the
claimant's decedent. If such an action is brought through or on
behalf of a minor or incompetent, the term includes the
claimant's legal guardian.
(2) Durable good.--The term ''durable good'' means any
product, or any component of any such product, which--
(A)(i) has a normal life expectancy of 3 or more
years; or
(ii) is of a character subject to allowance for
depreciation under the Internal Revenue Code of 1986;
and
(B) is--
(i) used in a trade or business;
(ii) held for the production of income; or
(iii) sold or donated to a governmental or
private entity for the production of goods,
training, demonstration, or any other similar
purpose.
(3) State.--The term ''State'' means any State of the
United States, the District of Columbia, the Commonwealth of
Puerto Rico, the Northern Mariana Islands, the Virgin Islands,
Guam, American Samoa, any other territory or possession of the
United States, and any political subdivision of any of the
foregoing.

SEC. 4. EFFECTIVE DATE; APPLICATION OF ACT.

(a) Effective Date.--Except as provided in subsection (b), this Act
shall take effect on the date of the enactment of this Act without
regard to whether the damage to property or death or personal injury at
issue occurred before such date of enactment.
(b) Application of Act.--This Act shall not apply with respect to
civil actions commenced before the date of the enactment of this Act.

A:
Workplace Goods Job Growth and Competitiveness Act of 2001 - Prohibits the filing of a civil action against a manufacturer or seller of a durable good (except a motor vehicle, vessel, aircraft, or train that is used primarily to transport passengers for hire) more than 18 years after it was delivered to its first purchaser or lessee for: (1) damage to property arising out of an accident involving such good; or (2) damages for death or personal injury arising out of an accident involving such good if the claimant has received or is eligible to receive worker compensation and the injury does not involve a toxic harm (including, but not limited to, all asbestos-related harm). Declares that this Act: (1) shall not bar an action against a defendant who made an express warranty in writing as to the safety or life expectancy of a specific product which was longer than 18 years (except that this Act shall apply at the expiration of such warranty); and (2) does not supersede or modify any statute or common law that authorizes an action for civil damages, cost recovery, or any other form of relief for remediation of the environment.
****